BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9635539)

  • 1. How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients?
    Raad II; Abi-Said D; Rolston KV; Karl CL; Bodey GP
    Cancer; 1998 Jun; 82(12):2449-58. PubMed ID: 9635539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
    Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
    Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
    Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
    Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].
    Figuera A; Tomás JF; Hernández L; Jiménez ML; Peñarrubia MJ; del Rey MC; Arranz R; Cámara R; López-Lorenzo JL; Fernández-Rañada JM
    Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.
    Raad II; Whimbey EE; Rolston KV; Abi-Said D; Hachem RY; Pandya RG; Ghaddar HM; Karl CL; Bodey GP
    Cancer; 1996 Apr; 77(7):1386-94. PubMed ID: 8608520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.
    de la Rubia J; Montesinos P; Martino R; Jarque I; Rovira M; Vázquez L; López J; Batlle M; de la Cámara R; Juliá A; Lahuerta JJ; Debén G; Díaz J; García R; Sanz MA
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):512-6. PubMed ID: 19285640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients.
    Miller JA; Butler T; Beveridge RA; Kales AN; Binder RA; Smith LJ; Ueno WM; Milkovich G; Goldwater S; Marion A
    Clin Ther; 1993; 15(3):486-99. PubMed ID: 8364941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of three types of empirical antibiotherapy in patients with febrile neutropenia: imipenem-cilastatin versus ceftazidime-vancomycin versus ticarcillin-amikacin-vancomycin].
    Bosseray A; Nicolini F; Brion JP; Michallet M; Hollard D; Stahl JP; Micoud M
    Pathol Biol (Paris); 1992 Oct; 40(8):797-804. PubMed ID: 1484739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
    Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imipenem/cilastatin as empirical treatment of severe infections in compromised patients.
    Biglino A; Bonasso M; Gioannini P
    J Chemother; 1991 Jan; 3 Suppl 1():208-12. PubMed ID: 12041767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI; Fung CP; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high-dose chemotherapy: results of a randomized study.
    García-Sáenz JA; Martín M; Casado A; Pérez-Segura P; Manrique I; Flores L; Macias JA; Cámara JC; Perezagua C; Díaz-Rubio E
    Rev Esp Quimioter; 2002 Sep; 15(3):257-63. PubMed ID: 12582429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A;
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections.
    Hou F; Li J; Wu G; Zheng B; Chen Y; Gu J; Wang H; Huo L; Xue X; Jia C; Yin Y; Tian X; Ren S
    Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia.
    Joshi M; Metzler M; McCarthy M; Olvey S; Kassira W; Cooper A
    Respir Med; 2006 Sep; 100(9):1554-65. PubMed ID: 16487695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.
    Caldwell JW; Singh S; Johnson RH
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():129-34. PubMed ID: 10225583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination therapy of antibiotics and intravenous immunoglobulin].
    Masaoka T
    Nihon Rinsho; 2001 Apr; 59(4):781-4. PubMed ID: 11305006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurological complication during imipenem/cilastatin therapy in uraemic patients.
    Campise M
    Nephrol Dial Transplant; 1998 Jul; 13(7):1895-6. PubMed ID: 9681765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.